Product Images Lisdexamfetamine Dimesylate

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 16 images provide visual information about the product associated with Lisdexamfetamine Dimesylate NDC 0378-6854 by Mylan Pharmaceuticals Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Lisdexamfetamine Dimesylate Structural Formula - image 01

Lisdexamfetamine Dimesylate Structural Formula - image 01

Figure 1: Specific Populations* - image 02

Figure 1: Specific Populations* - image 02

Figure 2: Effect of Other Drugs on Lisdexamfetamine Dimesylate - image 03

Figure 2: Effect of Other Drugs on Lisdexamfetamine Dimesylate - image 03

Figure 3: Effect of Lisdexamfetamine Dimesylate on Other Drugs - image 04

Figure 3: Effect of Lisdexamfetamine Dimesylate on Other Drugs - image 04

Figure 4: LS Mean SKAMP Deportment Subscale Score by Treatment and Time-point for Children Ages 6 to 12 with ADHD After 1 Week of Double-Blind Treatment (Study 3) - image 05

Figure 4: LS Mean SKAMP Deportment Subscale Score by Treatment and Time-point for Children Ages 6 to 12 with ADHD After 1 Week of Double-Blind Treatment (Study 3) - image 05

Figure 5: Kaplan-Meier Estimated Proportion of Patients with Treatment Failure for Pediatric Patients Ages 6 to 17 (Study 6) - image 06

Figure 5: Kaplan-Meier Estimated Proportion of Patients with Treatment Failure for Pediatric Patients Ages 6 to 17 (Study 6) - image 06

Figure 6: LS Mean (SE) PERMP Total Score by Treatment and Time-point for Adults Ages 18 to 55 with ADHD after 1 Week of Double-Blind Treatment (Study 8) - image 07

Figure 6: LS Mean (SE) PERMP Total Score by Treatment and Time-point for Adults Ages 18 to 55 with ADHD after 1 Week of Double-Blind Treatment (Study 8) - image 07

Figure 7: Kaplan-Meier Estimated Proportion of Subjects with Relapse in Adults with ADHD (Study 9) - image 08

Figure 7: Kaplan-Meier Estimated Proportion of Subjects with Relapse in Adults with ADHD (Study 9) - image 08

Figure 8: Kaplan-Meier Estimated Proportion of Subjects with Relapse in Adults with BED (Study 13) - image 09

Figure 8: Kaplan-Meier Estimated Proportion of Subjects with Relapse in Adults with BED (Study 13) - image 09

Lisdexamfetamine Dimesylate Capsules 10 mg Bottle Label - image 10

Lisdexamfetamine Dimesylate Capsules 10 mg Bottle Label - image 10

Lisdexamfetamine Dimesylate Capsules 20 mg Bottle Label - image 11

Lisdexamfetamine Dimesylate Capsules 20 mg Bottle Label - image 11

Lisdexamfetamine Dimesylate Capsules 30 mg Bottle Label - image 12

Lisdexamfetamine Dimesylate Capsules 30 mg Bottle Label - image 12

Lisdexamfetamine Dimesylate Capsules 40 mg Bottle Label - image 13

Lisdexamfetamine Dimesylate Capsules 40 mg Bottle Label - image 13

Lisdexamfetamine Dimesylate Capsules 50 mg Bottle Label - image 14

Lisdexamfetamine Dimesylate Capsules 50 mg Bottle Label - image 14

Lisdexamfetamine Dimesylate Capsules 60 mg Bottle Label - image 15

Lisdexamfetamine Dimesylate Capsules 60 mg Bottle Label - image 15

Lisdexamfetamine Dimesylate Capsules 70 mg Bottle Label - image 16

Lisdexamfetamine Dimesylate Capsules 70 mg Bottle Label - image 16